Noel J. Clarke, Ph.D.
Affiliations: | 2001 | University of Houston, Houston, TX, United States |
Area:
Administration, Nursing, EducationGoogle:
"Noel Clarke"Parents
Sign in to add mentor| Amaury Nora | grad student | 2001 | University of Houston | |
| (Roles of management strategy and decision -making process on nine measures of institutional effectiveness perceived by administrators and faculty at a public four -year institution of higher education.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jones C, Gray S, Brown M, et al. (2024) Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials. European Urology Oncology |
| Dodkins J, Nossiter J, Cook A, et al. (2023) Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. European Urology Oncology |
| Gillessen S, Bossi A, Davis ID, et al. (2023) Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990). 185: 178-215 |
| Attard G, Parry M, Grist E, et al. (2023) Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. Research Square |
| Gillessen S, Bossi A, Davis ID, et al. (2022) Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology |
| Sachdeva A, Hart CA, Kim K, et al. (2022) Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer. British Journal of Cancer |
| Dodkins J, Morris M, Nossiter J, et al. (2022) Practicalities, challenges and solutions to delivering a national organisational survey of cancer service and processes: lessons from the National Prostate Cancer Audit. Journal of Cancer Policy. 100344 |
| Gillessen S, Armstrong A, Attard G, et al. (2022) Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology |
| Turco F, Armstrong A, Attard G, et al. (2022) Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022]. European Urology |
| Hussain M, Carducci MA, Clarke N, et al. (2022) Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200208 |